Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$32M
- −182.0% YoY · +18.9% QoQ
- EPS (diluted)
- −$0.26
- −100.0% YoY · +21.2% QoQ
Source: XBRL data from the Eledon Pharmaceuticals, Inc. (ELDN) Q2 2026 10-Q on SEC EDGAR. USD.
Eledon Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and YoY change not disclosed in provided MD&A
- Profitability margins not disclosed in provided MD&A
- Best-performing program kidney transplantation, BESTOW eGFR 69 vs 66 mL/min/1.73 m²
- Phase 3 kidney program planned for late 2026, requiring additional financing
- Funding risk could curtail operations or force liquidation if financing unavailable
Risk Factors
- Going-concern risk: $88.8 million liquidity and $471.9 million accumulated deficit, with funding insufficient for twelve months
- Clinical-development risk: tegoprubart’s Phase 3 kidney-transplant trial requires substantial additional capital
- Regulatory risk: FDA or foreign regulators may impose clinical holds or require additional safety studies
- Operational risk: manufacturing delays could postpone trials because commercial-scale production remains unproven
- Financial-market risk: FDIC-insured deposits represent less than 3% of cash and short-term investments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eledon Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.